Multicenter Postmarket Analysis of the Neuroform Atlas Stent for Stent-Assisted Coil Embolization of Intracranial Aneurysms

The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. On the basis of retrospective chart review from 11 academic centers, we analyzed patients treate...

Full description

Saved in:
Bibliographic Details
Published in:American journal of neuroradiology : AJNR 2020-06, Vol.41 (6), p.1037-1042
Main Authors: Burkhardt, J-K, Srinivasan, V, Srivatsan, A, Albuquerque, F, Ducruet, A F, Hendricks, B, Gross, B A, Jankowitz, B T, Thomas, A J, Ogilvy, C S, Maragkos, G A, Enriquez-Marulanda, A, Crowley, R W, Levitt, M R, Kim, L J, Griessenauer, C J, Schirmer, C M, Dalal, S, Piper, K, Mokin, M, Winkler, E A, Abla, A A, McDougall, C, Birnbaum, L, Mascitelli, J, Litao, M, Tanweer, O, Riina, H, Johnson, J, Chen, S, Kan, P
Format: Article
Language:English
Subjects:
Adult
Aged
Blood Vessel Prosthesis
Embolization, Therapeutic - instrumentation
Female
Humans
Interventional
Intracranial Aneurysm - therapy
Male
Middle Aged
Product Surveillance, Postmarketing
Retrospective Studies
Stents
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Neuroform Atlas is a new microstent to assist coil embolization of intracranial aneurysms that recently gained FDA approval. We present a postmarket multicenter analysis of the Neuroform Atlas stent. On the basis of retrospective chart review from 11 academic centers, we analyzed patients treated with the Neuroform Atlas after FDA exemption from January 2018 to June 2019. Clinical and radiologic parameters included patient demographics, aneurysm characteristics, stent parameters, complications, and outcomes at discharge and last follow-up. Overall, 128 aneurysms in 128 patients (median age, 62 years) were treated with 138 stents. Risk factors included smoking (59.4%), multiple aneurysms (27.3%), and family history of aneurysms (16.4%). Most patients were treated electively (93.7%), and 8 (6.3%) underwent treatment within 2 weeks of subarachnoid hemorrhage. Previous aneurysm treatment failure was present in 21% of cases. Wide-neck aneurysms (80.5%), small aneurysm size (
ISSN:0195-6108
1936-959X
DOI:10.3174/ajnr.a6581